164 related articles for article (PubMed ID: 10913809)
1. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.
Mick R; Crowley JJ; Carroll RJ
Control Clin Trials; 2000 Aug; 21(4):343-59. PubMed ID: 10913809
[TBL] [Abstract][Full Text] [Related]
2. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
3. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
4. Statistical controversies in clinical research: should schedules of tumor size assessments be changed?
Filleron T; Kouokam W; Gilhodes J; Duhamel A; Penel N; Joly F; Tresch-Bruneel E; Kramar A; Houédé N
Ann Oncol; 2016 Nov; 27(11):1981-1987. PubMed ID: 27502711
[TBL] [Abstract][Full Text] [Related]
5. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
Kocherginsky M; Cohen EE; Karrison T
J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
[TBL] [Abstract][Full Text] [Related]
6. Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.
Goffin JR; Pond GR
BMC Med Res Methodol; 2011 Dec; 11():164. PubMed ID: 22151297
[TBL] [Abstract][Full Text] [Related]
7. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.
Texier M; Rotolo F; Ducreux M; Bouché O; Pignon JP; Michiels S
Comput Math Methods Med; 2018; 2018():1672176. PubMed ID: 29568321
[TBL] [Abstract][Full Text] [Related]
9. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
Kovalchik S; Mietlowski W
Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
[TBL] [Abstract][Full Text] [Related]
10. Phase II stopping rules that employ response rates and early progression.
Goffin JR; Tu D
J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
[TBL] [Abstract][Full Text] [Related]
11. Endpoints for agents that slow tumor growth.
Yu RX; Holmgren E
Contemp Clin Trials; 2007 Jan; 28(1):18-24. PubMed ID: 16829208
[TBL] [Abstract][Full Text] [Related]
12. Monitoring event times in early phase clinical trials: some practical issues.
Thall PF; Wooten LH; Tannir NM
Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
[TBL] [Abstract][Full Text] [Related]
13. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial designs for cytostatic agents: are new approaches needed?
Korn EL; Arbuck SG; Pluda JM; Simon R; Kaplan RS; Christian MC
J Clin Oncol; 2001 Jan; 19(1):265-72. PubMed ID: 11134222
[TBL] [Abstract][Full Text] [Related]
15. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
16. Sequential design of phase II-III cancer trials.
Lai TL; Lavori PW; Shih MC
Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
18. One-stage and two-stage designs for phase II clinical trials with survival endpoints.
Whitehead J
Stat Med; 2014 Sep; 33(22):3830-43. PubMed ID: 24817473
[TBL] [Abstract][Full Text] [Related]
19. General and statistical hierarchy of appropriate biologic endpoints.
Sargent D
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
[TBL] [Abstract][Full Text] [Related]
20. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
Fazzari M; Heller G; Scher HI
Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
